Last update 21 Nov 2024

IBC-0966

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Target
CD47 x PDL1 x SIRPα
Mechanism
CD47 inhibitors(Cluster of differentiation 47 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), SIRPα inhibitors(Signal-regulatory protein alpha inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Advanced cancerNeoplasmsNon-Hodgkin Lymphoma+ [1]
Inactive Indication-
Originator Organization
Beijing Sunho Pharmaceutical Co., Ltd.Beijing Sunho Pharmaceutical Co., Ltd.
Active Organization
Sunho (China) Biopharmaceutical Co., Ltd.Beijing Sunho Pharmaceutical Co., Ltd.Beijing Sunho Pharmaceutical Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with IBC-0966
CTR20211609 / RecruitingPhase 1/2
评估IBC0966在晚期恶性肿瘤受试者中的安全性、耐受性与有效性的I/IIa期临床研究
[Translation] Phase I/IIa clinical study to evaluate the safety, tolerability and efficacy of IBC0966 in subjects with advanced malignancies
NCT04980690 / RecruitingPhase 1/2
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors
100 Clinical Results associated with IBC-0966
Login to view more data
100 Translational Medicine associated with IBC-0966
Login to view more data
100 Patents (Medical) associated with IBC-0966
Login to view more data
100 Deals associated with IBC-0966
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 2
CN
Sunho (China) Biopharmaceutical Co., Ltd.
31 Aug 2021
NeoplasmsPhase 2
CN
Beijing Sunho Pharmaceutical Co., Ltd.Beijing Sunho Pharmaceutical Co., Ltd.
31 Aug 2021
Non-Hodgkin LymphomaPhase 1
CN
Sunho (China) Biopharmaceutical Co., Ltd.
30 Jan 2022
Non-Hodgkin LymphomaPhase 1
US
Sunho (China) Biopharmaceutical Co., Ltd.
30 Jan 2022
Solid tumorPhase 1
US
Sunho (China) Biopharmaceutical Co., Ltd.
30 Jan 2022
Solid tumorPhase 1
CN
Sunho (China) Biopharmaceutical Co., Ltd.
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free